FDA decision for Gilead’s once daily HIV pill BIC/LEN, PDUFA date August 27, 2026

Quick Trade Info Upcoming catalyst FDA PDUFA decision on bictegravir 75 mg plus lenacapavir 50 mg (BIC/LEN) for HIV treatment. Thursday, August 27, 2026. The FDA does not publish a decision time. Main stock affected GILD, Gilead Sciences, Inc. Live data verification $145.17 last, timestamp 2026-08-20 17:36:37 UTC, regular session. Expected stock reaction Positive. Pre-news action Buy. High probability of approval supported by two positive Phase 3 switch studies and priority review. Defined risk with partial size or a call spread. Catalyst confidence High that a decision occurs on August 27. Moderate risk of a short extension if last‑minute labeling or CMC items arise. Stock-reaction confidence Medium. Gilead is large cap, so the move should be modest but positive if approval is clean. More Info When the market will react Primary reaction on Thursday, August 27, 2026, either intraday if a press release posts during market hours, or after hours with price discovery in the next trading session. Follow through over 1 to 3 sessions as analysts update models. Fundamental effect Adds a new branded switch option that can extend Gilead’s HIV leadership. BIC/LEN targets virologically suppressed patients who want a simpler daily pill. Approval can slow competitor share gains and lengthen the revenue tail of the HIV franchise. Market expectations and forecast Expectation: approval on first cycle. Evidence: priority review granted, and Phase 3 ARTISTRY-1 and ARTISTRY-2 met noninferiority at 48 weeks with very low virologic failure rates near 1 percent. Historical NDA to approval rates are about 90 percent across diseases, and roughly 93 percent for infectious disease filings. My base case approval probability is 85 to 90 percent. Recent stock setup Shares rose after Q2 2026 results and guidance raise in early August, with HIV sales strength highlighted. Volume expanded on earnings. Peers in HIV, like GSK’s US ADR and Merck, have traded mixed in August. Priced-in level Medium. The date is public and partially in models, but numbers do not include launch contribution and label specifics. The prior move was mostly about earnings, not this decision. Expected move Options for the week around the date imply roughly a 4.5 to 5.5 percent one week move. Example math: price 145, implied volatility near 37 to 40 percent, time 7 days. 145 × 0.38 × sqrt(7/365) ≈ 7.6 points, about 5 percent. Surprise required A clean approval without restrictive labeling or drug interaction limits, plus early launch timing, would be needed for an upside move beyond about 5 percent. Any delay or Complete Response Letter would likely exceed the downside implied move. Positive scenario Approval with a broad switch label for virologically suppressed adults, no REMS beyond standard, and manageable drug interaction language. Management guides to a near term launch timeline and reiterates HIV growth of high single digits or better. Neutral scenario Approval, but with notable drug interaction or population carve outs that limit near term uptake. Street waits for formulary wins and early script data before re rating. Negative scenario PDUFA extension by three months due to new submissions late in the cycle, a manufacturing or labeling issue, or a Complete Response Letter requesting more data. Stock gives back recent strength. Why the stock is connected This is Gilead’s own NDA. A yes adds a new daily pill that combines bictegravir, a leading integrase inhibitor, with lenacapavir, a capsid inhibitor already approved in other settings. The switch population is large in HIV care. Even modest penetration can add meaningful revenue and protect the core Biktarvy base. Simple example: if 1 out of every 20 Biktarvy patients eventually switches to BIC/LEN, Gilead still keeps that patient on a Gilead regimen instead of risking a move to a rival. Other affected stocks MRK, as the key partner and competitor in long acting HIV regimens including once weekly oral programs. GSK, via ViiV Healthcare’s HIV portfolio, as a competitor in treatment and prevention. Impact strength and duration Medium impact, long term. The stock move should be modest on day one, but the revenue and share defense effects build over multiple years. Underappreciated factor Cannibalization can still be a net positive. Moving a patient from Biktarvy to BIC/LEN keeps revenue inside Gilead and may extend the brand life against weekly oral and injectable competitors. Also, if the drug interaction section is cleaner than expected, payers may be quicker to adopt. Post-news confirmation plan If approved, look for a close above 147 on at least 1.5 times the 20 day average volume. That would confirm demand. Hold 2 to 6 weeks while watching early access, payer updates, and first script color. Main risks A three month PDUFA extension. Label restrictions, especially around CYP3A inducer interactions with lenacapavir, that slow uptake. Manufacturing or supply issues. A broader rotation out of large cap pharma that overwhelms single stock news. Any other important factors 1) Timing of the press release matters for gap risk. Size positions accordingly. 2) If you prefer defined risk, a September monthly 145 by 155 call spread targets a 4 to 6 percent move while capping downside to the debit. 3) Watch competitors’ commentary. If rivals guide to faster share gains, some approval benefit could be offset.